Publication | Open Access
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
84
Citations
21
References
2021
Year
Lymphoid NeoplasiaMedicineCamidanlumab TesirineImmune Checkpoint InhibitorImmunotherapyOncologyRadiation OncologyPhase 1Refractory Lymphoma
| Year | Citations | |
|---|---|---|
Page 1
Page 1